Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$7.18 +1.1%	$5.81	$3.72 ▼ $12.61	$808.38M	1.82	1.33 million shs	1.98 million shs
NKTX Nkarta	$1.66	$1.87	$1.31 ▼ $8.23	$117.79M	0.72	1.03 million shs	505,102 shs
RLAY Relay Therapeutics	$3.46 +4.8%	$3.14	$1.78 ▼ $10.72	$565.77M	1.59	2.09 million shs	1.49 million shs
VALN Valneva	$5.67 -2.2%	$6.26	$3.62 ▼ $8.66	$493.55M	1.81	42,527 shs	11,452 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	+1.13%	-1.10%	+33.46%	+24.01%	-14.83%
NKTX Nkarta	0.00%	-4.87%	-5.41%	-10.03%	-71.91%
RLAY Relay Therapeutics	+4.85%	+7.12%	+14.95%	+40.08%	-46.93%
VALN Valneva	-2.24%	+1.98%	-9.71%	-16.12%	-19.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COGT Cogent Biosciences	2.5089 of 5 stars	4.4	1.0	2.7	0.0	0.6
NKTX Nkarta	2.2273 of 5 stars	3.6	1.0	2.6	1.7	0.6
RLAY Relay Therapeutics	2.8908 of 5 stars	3.4	2.0	3.4	2.5	0.6
VALN Valneva	2.003 of 5 stars	3.5	3.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.75	Moderate Buy	$14.43	100.96% Upside
NKTX Nkarta	3.13	Buy	$14.33	763.45% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	410.60% Upside
VALN Valneva	3.00	Buy	$15.50	173.37% Upside

Current Analyst Ratings Breakdown

Latest NKTX, COGT, RLAY, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
RLAY Relay Therapeutics	$10.01M	59.26	N/A	N/A	$4.65 per share	0.74
VALN Valneva	$183.52M	2.63	$0.10 per share	59.36	$2.41 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
VALN Valneva	-$13.25M	-$1.19	N/A	N/A	N/A	-43.08%	-43.05%	-16.23%	8/12/2025 (Estimated)

Latest NKTX, COGT, RLAY, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	N/A	5.13	5.13
NKTX Nkarta	N/A	14.48	14.48
RLAY Relay Therapeutics	N/A	19.96	19.96
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
NKTX Nkarta	80.54%
RLAY Relay Therapeutics	96.98%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	7.29%
NKTX Nkarta	8.40%
RLAY Relay Therapeutics	4.32%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	164.04 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

NKTX, COGT, RLAY, and VALN Headlines

Recent News About These Companies

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

June 26, 2025 | globenewswire.com

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

June 25, 2025 | globenewswire.com

Valneva Scotland earns prestigious global health and safety award

June 24, 2025 | msn.com

Valneva (NASDAQ:VALN) Shares Gap Down - Should You Sell?

June 17, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

June 14, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Stock Price Down 4% - Here's What Happened

June 12, 2025 | marketbeat.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.inI

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.comP

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

June 3, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Decrease in Short Interest

June 2, 2025 | marketbeat.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.comI

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, COGT, RLAY, and VALN Company Descriptions

Cogent Biosciences NASDAQ:COGT

$7.18 +0.08 (+1.13%)

As of 06/30/2025 04:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Nkarta NASDAQ:NKTX

$1.66 0.00 (0.00%)

As of 06/30/2025 04:00 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Relay Therapeutics NASDAQ:RLAY

$3.46 +0.16 (+4.85%)

As of 06/30/2025 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Valneva NASDAQ:VALN

$5.67 -0.13 (-2.24%)

As of 06/30/2025 03:49 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time